91AV

Introduction

• Deepen your understanding of the complex aspects in valuation of products, companies and technology platforms
• Listen to best practice examples from pharmaceutical and biotech companies, their strategies and tools to master challenges like pricing and reimbursement
• Hear about the different valuation models of early stage products versus late stage products

Companies and institutes invited to speak:
• AstraZeneca AB
• Merck and Co.
• Bayer Pharma AG
• Novartis AG
• Hoffmann-La Roche Ltd.
• Medivir AB
• Avance
• Gilead Sciences, Inc.
• Boehringer Ingelheim GmbH
• Sanofi S.A.
• Bayer Schering Pharma AG
• Polyphor Ltd.
• Grünenthal GmbH
• Novo Nordisk A/S
• Merck Serono
• Amgen, Inc.
• Pfizer, Inc.
• Astellas Pharma, Inc.
• MorphoSys AG
• UCB Pharma Ltd.

Useful links

Speakers

• Dr. Kay Brickmann Business Development Director Scientific Partnering and Alliances - AstraZeneca AB, Sweden
• Morten Faester Director Business Development - Medivir AB, Sweden
• Ralph Villiger Managing Director - Avance , Switzerland

---

Venue

Movenpick Hotel Berlin

Movenpick Hotel Berlin, Schoneberger Strasse 3, Berlin, 10963, Germany

Committee

• IQPC Germany IQPC provides a number of opportunities in becoming partners through speaking, sponsorship, or media partnerships., Germany

---

Organised by

IQPC Germany

Contact information

IQPC Germany
IQPC Germany
Friedrichstrasse 94, 10117 Berlin
+49 (0)30 20913 274
Contact us by email

---